Is a ChondroFiller injection suitable for thumb or finger joint damage?

For many patients with thumb or finger joint pain, the first practical question is straightforward: does this treatment apply to my joint, and does it suit the type of damage I have?

ChondroFiller injection is used for focal cartilage defects and osteoarthritis in the small joints of the hand. The basal thumb joint — the trapeziometacarpal (TMC or CMC-1) joint at the base of the thumb — is the most clinically studied small hand joint for this treatment. Published data cover the full Eaton-Littler spectrum, from early-stage (I–II) to advanced-stage (III–IV) OA, which means a formal diagnosis of moderate or even significant thumb base arthritis does not automatically exclude someone from consideration.

The wrist represents a feasibility-confirmed adjacent indication: published arthroscopy-assisted data from a 2025 prospective study (Matta et al.) demonstrated safe, effective application in highly constrained wrist cartilage defects using very small volumes — confirming that the scaffold can be placed precisely in tight hand-joint spaces.

Finger joints (PIP and DIP) represent a plausible extension given the anatomy and the wrist feasibility findings, though no dedicated published trial exists yet for those specific joints.

Across all these sites, the treatment tends to perform better when some cartilage remains. Severely end-stage joint destruction — where cartilage has been lost entirely — is a recognised limiting factor based on experience in other load-bearing joints.

The procedure is delivered as an ultrasound-guided outpatient injection, not surgery, under local anaesthesia. The sections below set out the clinical evidence in detail.

What the clinical evidence shows for basal thumb OA

The Corain et al. (2023) prospective study provides the primary clinical reference for this indication. Forty-three patients with trapeziometacarpal osteoarthritis received a single intra-articular ChondroFiller injection under image guidance, stratified by OA severity — Eaton-Littler Stages I–II in Group A, Stages III–IV in Group B.

At both 30 days and 6 months post-injection, both groups achieved highly significant improvements across three independent outcome measures: pain on the Numerical Rating Scale (NRS), upper limb disability on the DASH questionnaire, and hand strength on Jamar grip and pinch testing. The breadth of that benefit — spanning the early and advanced cohorts — is clinically notable, though experience with ChondroFiller in other load-bearing joints suggests that patients who still have meaningful residual cartilage tend to produce more reliable repair.

Beyond symptom relief — what the MRI data showed

Post-treatment MRI confirmed that the benefit extended beyond pain control to measurable structural change: reduced bone marrow oedema, diminished periarticular effusion, and visible widening of the trapeziometacarpal joint space were all recorded at follow-up. For patients asking whether ChondroFiller injection addresses the underlying joint biology or simply masks discomfort, this imaging evidence is directly relevant — the two outcomes were tracked separately, and both were recorded.

What the study does and does not establish

The Corain study is a single-arm prospective study, not a randomised controlled trial. That is the honest description of the current published evidence for thumb CMC OA specifically: prospective, with pre-defined outcome measures, but without a concurrent comparator group. Independent follow-up data beyond six months for the trapeziometacarpal joint have not yet been published. The Corain findings represent the strongest available thumb-specific evidence — and a significant and sustained benefit at six months is a meaningful result — but they sit at the start of an evidence programme rather than the end of one.

How ChondroFiller works inside a small joint

Unlike a steroid injection, which reduces inflammation, or hyaluronic acid, which lubricates the joint temporarily, ChondroFiller works through a fundamentally different mechanism — one that aims to support the body's own repair process rather than simply mask symptoms.

The technical term is acellular matrix-induced chondrogenesis: the scaffold provides the architecture; the patient's own cells do the repair work. There are no donor cells in the product. What is injected is a purified Type I collagen solution — the same structural protein found in connective tissue — that arrives as a liquid and self-gels within minutes once inside the joint space. This in-situ polymerisation means the material conforms to the defect and stays where it is placed, without requiring open surgery or precise pre-shaping.

Once the scaffold has set, it acts as a chemotactic matrix — a term that refers to its ability to attract cells towards it. Progenitor and stem cells from the surrounding synovium and subchondral bone migrate into the scaffold and, in the presence of this collagen environment, begin to differentiate along a chondrogenic pathway, producing cartilage-specific matrix proteins. A 2025 ex vivo explant study provided mechanistic support for this process: ChondroFiller scaffolds showed a 2.4-fold increase in DNA content by day 14, indicating meaningful cellular recruitment into the material. This is laboratory evidence rather than proof of clinical cartilage regrowth, but it grounds the recruitment claim in measurable biology.

As host cells populate the scaffold and lay down new matrix, the collagen scaffold itself is gradually resorbed. Nothing permanent remains in the joint. For patients who ask whether they are being implanted with a lasting foreign material, the answer is no — the goal is to leave behind host-derived tissue once the scaffold has served its purpose.

How the injection is placed in thumb and small hand joints

On the day of treatment, the procedure takes place in an outpatient clinic rather than an operating theatre. No general anaesthetic is required — a local anaesthetic is applied to numb the area before the injection is given, and patients go home the same day without hospital admission.

Ultrasound guidance is central to the technique, and in the thumb and finger joints it is particularly important. The basal thumb joint and the small interphalangeal joints offer considerably less space than a knee or hip, which means the margin for imprecise placement is narrow. Image guidance allows the clinician to visualise the joint in real time, confirming needle position before the collagen scaffold is introduced.

Why volume precision matters

Data from the 2025 Matta wrist study offer a direct lesson for small-joint technique. In that series, ChondroFiller was delivered via fine-bore G20–21 cannulas in volumes of only 0.2–0.3 mL per defect. Follow-up arthroscopy found that applications placed flush with the cartilage surface healed cleanly; overfilled defects, by contrast, produced fibrous tissue rather than chondrogenic repair. The implication is clear: in a constrained joint, too much material is counterproductive. This is one reason the procedure is performed by a clinician experienced in image-guided joint injection rather than as a routine outpatient referral.

After the injection

Patients should expect a period of activity restriction following treatment. ChondroFiller does not have immediate mechanical stiffness — the scaffold needs time to consolidate before the joint is loaded — and the hand is one of the most frequently used structures in daily life. Resting the hand in the hours and days after injection is a standard post-procedure instruction, not a sign that something has gone wrong. The treating clinician will advise on the appropriate duration based on the joint treated and the patient's activities.

Who is most likely to benefit — and what affects results

Deciding whether a patient is a good candidate comes down to three factors: how much cartilage remains, the anatomy of the specific joint, and how the hand is used day to day.

OA severity and the cartilage-first principle

The Corain study enrolled patients across the full Eaton-Littler range — from Stage I–II through to Stage III–IV — and both groups showed meaningful improvement. That breadth is reassuring, but data from broader ChondroFiller experience introduces an important nuance. In hip studies, patients with higher-grade pre-existing osteoarthritis (Tönnis Grade 2–3) consistently produced poorer outcomes than those with more cartilage intact. The working principle that emerges is straightforward: the scaffold recruits cells and supports repair, but it cannot substitute for cartilage that is entirely absent. Patients who still have some residual articular surface — including those with post-traumatic chondral defects in the thumb or wrist — are better placed to benefit. Patients with end-stage, bone-on-bone joint destruction are unlikely to be suitable candidates. A clinical assessment, including imaging, is needed to confirm which category applies.

Hand use and loading

Patients in physically demanding occupations — manual workers, musicians, and others who rely heavily on fine grip — should factor in a longer recovery window after injection. As covered in the previous section, the scaffold is mechanically vulnerable during the consolidation phase; in high-use hand joints, the clinical advice on activity restriction is likely to be correspondingly cautious.

Finger joints — the evidence gap

For the PIP and DIP joints specifically, the small-joint feasibility demonstrated in the wrist dataset provides an adjacent technical rationale, but no published clinical trial has enrolled finger-joint patients directly. Patients considering ChondroFiller injection for finger OA should be aware they are working from informed extrapolation rather than a dedicated evidence base — and a thorough clinical assessment remains the only way to determine individual suitability.

Accessing ChondroFiller injection in London

For patients in London and the surrounding area, Liquid Cartilage™ (ChondroFiller injection) is available at the London Cartilage Clinic on Harley Street — the UK's certified delivery centre for the product.

Professor Paul Y. F. Lee leads delivery of the treatment in the UK. In the context of thumb and small hand joint injection, where precise volume placement directly affects outcome, clinical experience with image-guided technique in constrained joints is a material consideration.

The first step is a clinical assessment rather than a treatment booking. That assessment typically involves a review of any available imaging, a symptom and staging discussion, and confirmation that the joint anatomy and OA grade are suitable for the injectable scaffold pathway. No hospital admission is required at any stage — the procedure itself is carried out in an outpatient setting on the same visit.

To find out whether ChondroFiller injection is the right option for your joint, book an assessment at londoncartilage.com.

1. [1] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Platelet-Rich Plasma Injection for Thumb Carpometacarpal Joint Osteoarthritis. (2023). https://doi.org/10.1016/j.arrct.2023.100257 https://doi.org/10.1016/j.arrct.2023.100257
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759